EGFR and non-small cell lung carcinoma: EGFR inhibitors, epitomized by erlotinib [97], [98], gefitinib [99], [100], and Osimertinib [101], [102], have ushered in a revolutionary transformation in the therapeutic landscape of non-small cell lung cancer (NSCLC).